Equities

Linical Co Ltd

2183:TYO

Linical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)400.00
  • Today's Change2.00 / 0.50%
  • Shares traded20.20k
  • 1 Year change-41.86%
  • Beta0.7057
Data delayed at least 20 minutes, as of Sep 20 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of JPY
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
ASSETS
Cash And Short Term Investments7,4657,0425,986
Total Receivables, Net3,4423,4152,883
Total Inventory------
Prepaid expenses1,5211,2811,186
Other current assets, total321271267
Total current assets12,74912,00910,321
Property, plant & equipment, net519625664
Goodwill, net3,5483,3843,407
Intangibles, net117127159
Long term investments272373348
Note receivable - long term------
Other long term assets385374366
Total assets18,54017,46515,716
LIABILITIES
Accounts payable------
Accrued expenses571622613
Notes payable/short-term debt600600600
Current portion long-term debt/capital leases597630628
Other current liabilities, total6,0004,8833,637
Total current liabilities7,7696,7365,478
Total long term debt1,8052,4022,965
Total debt3,0023,6324,193
Deferred income tax------
Minority interest------
Other liabilities, total731746731
Total liabilities10,3059,8839,173
SHAREHOLDERS EQUITY
Common stock214214214
Additional paid-in capital------
Retained earnings (accumulated deficit)7,3157,2936,605
Treasury stock - common(657)(657)(657)
Unrealized gain (loss)267842
Other equity, total1,338653339
Total equity8,2357,5816,543
Total liabilities & shareholders' equity18,54017,46515,716
Total common shares outstanding232323
Treasury shares - common primary issue2.152.152.15
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.